Manage episode 463658939 series 3642897
Content provided by Celesta Capital | Deep Tech Venture Capital Firm. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Celesta Capital | Deep Tech Venture Capital Firm or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Driven both by surging demand and rapid technology advancements, an emerging area of health innovation called “bioconvergence” is driving improvements in human health and sustained interest from investors. This episode will explore these new applications merging engineered technologies with scientific disciplines, including in diagnostics, therapeutics, and elsewhere.
Nobel Laureate Dr. Jim Rothman, Dr. Melanie Mathieu of Prellis Biologics, and Daniel Dornbusch of Excision join host Michael Marks for an in-depth discussion covering advancements in CRISPR technology, the role of AI in drug discovery, the future of personalized medicine, and much more.
26 episodes